# Seminar 04: First Trimester Complications ## Year 3: Obstetrics and Gynecology Clerkship --- ## Learning Objectives By the end of this seminar, students will be able to: 1. Evaluate first trimester vaginal bleeding 2. Diagnose and manage ectopic pregnancy 3. Recognize types of spontaneous abortion 4. Describe molar pregnancy 5. Manage hyperemesis gravidarum 6. Identify early pregnancy loss options --- ## Seminar Outline ### I. Approach to First Trimester Bleeding First trimester vaginal bleeding is remarkably common, occurring in 20-40% of all pregnancies, and requires systematic evaluation to determine etiology and appropriate management. While approximately half of pregnancies with first trimester bleeding continue to viable delivery, the bleeding may herald serious conditions including ectopic pregnancy, miscarriage, or gestational trophoblastic disease. The clinical approach must balance thorough evaluation to identify emergent conditions with appropriate reassurance for patients with benign causes. Understanding that many patients with first trimester bleeding will have normal pregnancy outcomes helps guide counseling and management decisions. The differential diagnosis of first trimester bleeding encompasses pregnancy-related and non-pregnancy-related causes that must be systematically considered. Pregnancy-related causes include ectopic pregnancy, various types of spontaneous abortion, and gestational trophoblastic disease, each requiring different management approaches. Implantation bleeding, a normal phenomenon occurring when the blastocyst implants into the endometrium, typically causes light spotting around the expected time of menses. Cervical causes including cervicitis, ectropion, and polyps may cause bleeding, particularly following intercourse. Vaginal or vulvar sources should also be considered and can often be identified on speculum examination. Initial evaluation of first trimester bleeding requires a focused history, careful physical examination, and targeted laboratory and imaging studies. History should include last menstrual period, quantification of bleeding amount and duration, associated pain or cramping, and prior pregnancy history including ectopic pregnancies. Vital signs assessment evaluates hemodynamic stability, as unstable patients may have ruptured ectopic pregnancy or hemorrhage requiring emergent intervention. Speculum examination identifies the bleeding source, assesses whether the cervical os is open or closed, and allows visualization of products of conception if present. Laboratory evaluation includes quantitative beta-hCG, Rh type for potential RhoGAM administration, and complete blood count to assess for anemia. Interpretation of beta-hCG levels and their correlation with ultrasound findings guides diagnostic decision-making. The discriminatory zone, typically 1500-2000 mIU/mL, represents the beta-hCG level at which an intrauterine pregnancy should be visible on transvaginal ultrasound. Normal early pregnancy demonstrates beta-hCG doubling every 48-72 hours, though the rate slows as levels increase. An abnormally slow rise or plateau in beta-hCG suggests ectopic pregnancy or non-viable intrauterine pregnancy. Falling beta-hCG levels indicate pregnancy loss, whether from spontaneous abortion or resolving ectopic pregnancy, and should be followed to undetectable levels. Panel A: Pie chart showing outcomes of first trimester bleeding with approximately 50% continuing to viable pregnancy and distribution of adverse outcomes. Panel B: Differential diagnosis algorithm organized by pregnancy-related (ectopic, miscarriage, molar) versus cervical/vaginal causes. Panel C: Step-wise evaluation flowchart from history through physical examination, laboratory studies, and imaging. Panel D: Graph illustrating beta-hCG discriminatory zone concept with expected doubling times and abnormal patterns suggesting ectopic or non-viable pregnancy. --- ### II. Ectopic Pregnancy Ectopic pregnancy occurs when implantation takes place outside the uterine cavity and represents a potentially life-threatening condition requiring prompt diagnosis and treatment. Risk factors include prior ectopic pregnancy (the strongest predictor), prior tubal surgery or sterilization, history of pelvic inflammatory disease causing tubal damage, and use of assisted reproductive technologies. Intrauterine device use does not increase ectopic risk but, if pregnancy occurs with an IUD in place, the probability that it is ectopic is higher than in the general pregnant population. Smoking impairs ciliary function and tubal motility, increasing ectopic risk. The clinical presentation of ectopic pregnancy varies from asymptomatic early cases to catastrophic presentations with rupture and hemorrhage. Vaginal bleeding, typically light, occurs in most cases and often precedes the diagnosis. Unilateral pelvic or abdominal pain may precede bleeding and localizes to the side of the ectopic. Ruptured ectopic pregnancy presents with sudden severe abdominal pain, hypotension, tachycardia, and signs of peritoneal irritation. Shoulder pain from diaphragmatic irritation by hemoperitoneum suggests significant intra-abdominal bleeding. Physical examination may reveal adnexal tenderness, palpable mass, or cervical motion tenderness. Diagnosis of ectopic pregnancy relies on the correlation of beta-hCG levels with transvaginal ultrasound findings. When beta-hCG exceeds the discriminatory zone and no intrauterine pregnancy is identified on transvaginal ultrasound, ectopic pregnancy is highly suspected. An adnexal mass separate from the ovary, particularly with a tubal ring appearance, strongly suggests ectopic pregnancy. Free fluid in the pelvis indicates rupture with hemoperitoneum. Approximately 95% of ectopic pregnancies occur in the fallopian tube, with the ampullary segment being the most common location, though interstitial, cervical, ovarian, and abdominal ectopics also occur. The diagnostic algorithm integrates beta-hCG levels, ultrasound findings, and clinical stability to guide management. When beta-hCG is above the discriminatory zone and an intrauterine pregnancy is confirmed, ectopic is essentially excluded. Above the discriminatory zone with no intrauterine pregnancy suggests ectopic or recent complete abortion. Below the discriminatory zone with no visible pregnancy requires serial beta-hCG measurement and repeat ultrasound as levels rise. Any patient with an adnexal mass or significant free fluid should be considered to have an ectopic pregnancy until proven otherwise, regardless of beta-hCG level. Panel A: Risk factor diagram showing prior ectopic as highest risk, followed by tubal surgery, PID history, IUD with pregnancy, ART, and smoking with relative risk estimates. Panel B: Clinical presentation spectrum from asymptomatic through classic triad (bleeding, pain, amenorrhea) to ruptured with hemodynamic instability. Panel C: Ultrasound images showing empty uterus with discriminatory zone beta-hCG, tubal ring sign, and free fluid in posterior cul-de-sac. Panel D: Diagnostic algorithm flowchart integrating beta-hCG levels with ultrasound findings and clinical stability to determine management pathway. --- ### III. Ectopic Pregnancy Management Medical management with methotrexate is appropriate for hemodynamically stable patients meeting specific criteria. Candidates must be hemodynamically stable with no signs of rupture, have beta-hCG generally less than 5000 mIU/mL (though some protocols allow higher levels), ectopic size less than 3-4 cm, and no fetal cardiac activity visible on ultrasound. The patient must be able to comply with close follow-up requirements. The single-dose protocol administers methotrexate 50 mg/m2 intramuscularly, with beta-hCG measured on day 4 and day 7. Successful treatment is indicated by a 15% or greater decline in beta-hCG between days 4 and 7. Contraindications to methotrexate therapy identify patients who require surgical management. Absolute contraindications include hemodynamic instability or signs of rupture requiring immediate surgical intervention. Inability to return for follow-up precludes safe medical management. Breastfeeding women should not receive methotrexate due to excretion in breast milk. Methotrexate sensitivity or immunodeficiency states contraindicate use. Relative contraindications include beta-hCG greater than 5000 mIU/mL, ectopic size greater than 4 cm, or presence of fetal cardiac activity, all of which are associated with lower success rates of medical management. Surgical management is indicated for unstable patients, those who fail medical management, or when methotrexate is contraindicated. Ruptured ectopic pregnancy requires emergency surgical intervention, with laparoscopy preferred for stable patients and laparotomy for hemodynamically unstable patients. Salpingostomy, a linear incision to remove the ectopic while preserving the tube, is considered for patients desiring future fertility with a healthy contralateral tube. Salpingectomy, complete tube removal, is performed for patients who have completed childbearing, have recurrent ectopic in the same tube, or have severe tubal damage. Laparoscopy offers advantages of faster recovery and shorter hospital stay when patient stability permits. Follow-up after ectopic pregnancy treatment ensures complete resolution and counsels patients on future pregnancy. After methotrexate, serial weekly beta-hCG measurements continue until levels are undetectable, which may take several weeks. Patients should avoid alcohol, folate supplements, and non-steroidal anti-inflammatory drugs until resolution. Pregnancy should be avoided for at least three months after methotrexate to allow folate repletion. After surgical management, beta-hCG is followed to undetectable, and patients may attempt conception sooner. Future ectopic risk is approximately 10-15%, and patients should be counseled to seek early evaluation in subsequent pregnancies. Panel A: Methotrexate eligibility criteria checklist with stability requirements, beta-hCG threshold, size limitations, and cardiac activity assessment. Panel B: Single-dose methotrexate protocol timeline showing injection day, day 4 and day 7 beta-hCG measurements, and success criteria of greater than 15% decline. Panel C: Surgical decision tree showing salpingostomy versus salpingectomy indications based on future fertility desires, contralateral tube status, and degree of tubal damage. Panel D: Follow-up protocol comparison between medical and surgical management including beta-hCG monitoring, activity restrictions, and time to attempting conception. --- ### IV. Spontaneous Abortion (Miscarriage) Spontaneous abortion, medically defined as pregnancy loss before 20 weeks gestation, affects approximately 10-20% of clinically recognized pregnancies. Early losses occurring before 13 weeks account for approximately 80% of all spontaneous abortions, while late losses between 13 and 20 weeks are less common. Recurrent pregnancy loss, defined as two or three or more consecutive losses depending on guidelines, affects 1-2% of couples and warrants specialized evaluation. The terminology of spontaneous abortion, while medically accurate, is often replaced by the term miscarriage in patient communication due to the emotional connotations of the word abortion. Chromosomal abnormalities account for 50-60% of early pregnancy losses and represent the most common identifiable cause. Trisomies, particularly trisomy 16, are the most frequent chromosomal abnormality in miscarriage specimens. Maternal factors contributing to pregnancy loss include advanced maternal age, uterine anomalies, and poorly controlled thyroid disease. Immunologic factors, particularly antiphospholipid syndrome, cause pregnancy loss through placental thrombosis. Environmental factors including smoking, heavy alcohol use, and certain drugs increase miscarriage risk. Despite thorough evaluation, many pregnancy losses remain unexplained. The classification of spontaneous abortion guides clinical management and patient counseling. Threatened abortion presents with vaginal bleeding and a closed cervical os with a viable intrauterine pregnancy on ultrasound. Inevitable abortion shows an open cervix with products of conception still within the uterus. Incomplete abortion describes partial passage of products of conception with an open cervix and tissue remaining. Complete abortion indicates passage of all products with a closed cervix and empty uterus. Missed abortion refers to a non-viable pregnancy retained in the uterus with a closed cervical os, also termed early pregnancy loss or embryonic demise. Ultrasound criteria for diagnosing non-viable pregnancy have been established to avoid misdiagnosis of viable gestations. A crown-rump length of 7 mm or greater with no cardiac activity indicates non-viability. A gestational sac mean diameter of 25 mm or greater with no embryo (anembryonic gestation) indicates non-viability. When findings are less definitive, repeat ultrasound in 7-10 days allows confirmation before diagnosis. Early pregnancy viability is supported by appropriate growth between scans, visible yolk sac by expected time, and appropriate embryonic cardiac activity when crown-rump length reaches 5-7 mm. Panel A: Epidemiology diagram showing pregnancy loss rates by gestational age with 10-20% overall rate and higher proportion occurring before 13 weeks. Panel B: Pie chart of miscarriage etiologies with chromosomal abnormalities comprising 50-60%, maternal factors, immunologic factors, and unexplained. Panel C: Classification schema comparing threatened, inevitable, incomplete, complete, and missed abortion by cervical os status and pregnancy location. Panel D: Ultrasound diagnostic criteria showing CRL greater than 7 mm without cardiac activity and mean sac diameter greater than 25 mm without embryo as definitive non-viability findings. --- ### V. Miscarriage Management Expectant management allows spontaneous passage of pregnancy tissue and is appropriate for selected patients with early pregnancy loss. This approach is most successful for incomplete abortion where some tissue has already passed. For missed abortion, expectant management has variable success rates of 25-75% depending on gestational age and time allowed. Counseling includes that passage may take days to weeks and that cramping and bleeding will occur. Warning signs requiring urgent evaluation include heavy bleeding soaking more than two pads per hour, fever, or signs of infection. Follow-up ultrasound confirms complete passage of tissue. Medical management using misoprostol accelerates tissue passage and increases success rates compared with expectant management. The typical regimen is misoprostol 800 mcg administered vaginally, which may be repeated in 24-48 hours if initial passage is incomplete. Success rates of 80-90% within one to two weeks are achieved with this approach. Side effects include cramping, bleeding, and gastrointestinal symptoms including nausea and diarrhea. Mifepristone pretreatment 24-48 hours before misoprostol increases efficacy. Patients are counseled on expected bleeding patterns and when to seek emergent care, and follow-up ultrasound confirms complete evacuation. Surgical management with dilation and curettage (D&C) provides definitive treatment and is indicated in specific circumstances. Hemodynamic instability from heavy bleeding requires urgent surgical intervention. Infection, including septic abortion, necessitates prompt surgical evacuation combined with antibiotic therapy. Patient preference for definitive, rapid resolution is a valid indication. Failed expectant or medical management requires surgical completion. Tissue obtained at D&C can be sent for cytogenetic analysis in cases of recurrent loss. Complications include uterine perforation, cervical injury, infection, and Asherman syndrome from intrauterine adhesions. Emotional support and appropriate counseling form essential components of miscarriage care regardless of management approach. Acknowledging the loss and validating the patient's grief respects the significance of the pregnancy. Reassurance that the loss is not the patient's fault helps address common guilt and self-blame. Information about when to attempt subsequent pregnancy, typically after one normal menstrual cycle, guides future planning. Resources for support groups and counseling services should be offered. Rh-negative patients receive RhoGAM to prevent alloimmunization. Follow-up ensures physical recovery and provides opportunity to address ongoing emotional needs. Panel A: Expectant management candidacy criteria and success rates by abortion type, with counseling points about timeline and warning signs. Panel B: Medical management protocol showing misoprostol dosing, timing of repeat dose, and expected success rates with follow-up requirements. Panel C: Surgical management indications flowchart showing when D&C is required urgently (instability, sepsis) versus electively (patient preference, failed medical). Panel D: Comprehensive care diagram addressing emotional support elements, RhoGAM administration criteria, and follow-up timeline. --- ### VI. Recurrent Pregnancy Loss Recurrent pregnancy loss, now defined as two or more consecutive pregnancy losses, affects 1-2% of couples attempting pregnancy and warrants systematic evaluation. The traditional definition requiring three consecutive losses has been modified by many professional organizations to initiate evaluation after two losses, given the similar diagnostic yield and significant emotional burden. Primary recurrent loss refers to patients who have never achieved a viable pregnancy, while secondary recurrent loss occurs in patients with a prior viable pregnancy followed by consecutive losses. Evaluation aims to identify treatable causes while providing supportive care for the many couples with unexplained recurrent loss. The evaluation of recurrent pregnancy loss addresses parental, uterine, and immunologic factors. Parental karyotyping identifies balanced translocations or other chromosomal rearrangements present in 3-5% of couples with recurrent loss, which may result in unbalanced offspring. Uterine evaluation with pelvic ultrasound, saline infusion sonography, or hysteroscopy identifies structural abnormalities including septate uterus, submucosal fibroids, polyps, or intrauterine adhesions. Antiphospholipid antibody testing, including lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2 glycoprotein I antibodies, identifies this treatable cause in approximately 15% of affected patients. Thyroid-stimulating hormone assesses for thyroid dysfunction that may contribute to pregnancy loss. Identified causes and their treatments guide management of recurrent pregnancy loss. Antiphospholipid syndrome, when diagnosed by positive antibodies on two occasions 12 weeks apart with appropriate clinical criteria, is treated with low-dose aspirin and prophylactic heparin during subsequent pregnancies. Uterine septum resection via hysteroscopy may reduce pregnancy loss rates, though evidence is mixed. Thyroid dysfunction should be normalized with appropriate medication before and during pregnancy. Parental chromosomal abnormalities may be addressed through preimplantation genetic testing with in vitro fertilization or use of donor gametes, though many couples achieve successful pregnancy naturally despite carrying translocations. Unexplained recurrent pregnancy loss affects approximately 50% of couples despite thorough evaluation and, paradoxically, carries a favorable prognosis. The likelihood of successful subsequent pregnancy without specific treatment is 60-70% with supportive care alone. Empiric interventions including progesterone supplementation and aspirin are sometimes offered, though evidence for benefit is limited. Close monitoring and early ultrasound in subsequent pregnancies provide reassurance and early detection of complications. Emotional support acknowledges the anxiety and grief associated with pregnancy after loss. Referral to reproductive endocrinology may be appropriate for additional evaluation and treatment options. Panel A: Evaluation protocol flowchart showing parental karyotype, uterine assessment modalities, antiphospholipid antibody panel, and thyroid testing with diagnostic yield estimates. Panel B: Pie chart of identified causes showing parental chromosomal (3-5%), uterine anomaly (10-15%), antiphospholipid syndrome (15%), thyroid dysfunction, and unexplained (50%). Panel C: Treatment algorithm matching identified cause to specific intervention: APS treatment protocol, septum resection, thyroid normalization, and genetic counseling for translocations. Panel D: Prognosis counseling diagram showing 60-70% success rate with unexplained recurrent loss and supportive care components. --- ### VII. Gestational Trophoblastic Disease Gestational trophoblastic disease encompasses a spectrum of conditions arising from abnormal placental development ranging from benign molar pregnancy to malignant choriocarcinoma. Complete molar pregnancy results from fertilization of an empty egg by one or two sperm, producing diploid 46,XX or 46,XY tissue that is entirely paternal in origin, with no fetal development. Partial molar pregnancy occurs when a normal egg is fertilized by two sperm, creating triploid 69,XXY (most commonly) tissue with abnormal fetal development. Invasive mole represents local myometrial invasion by molar tissue. Choriocarcinoma is a highly malignant tumor that can metastasize widely. The distinction between complete and partial molar pregnancy has clinical and prognostic implications. Complete moles have entirely paternal diploid karyotype with no fetal tissue present, while partial moles have triploid karyotype with abnormal fetal parts present. Beta-hCG levels are markedly elevated in complete moles, often exceeding 100,000 mIU/mL, while partial moles show moderate elevation. Theca lutein cysts from hCG stimulation occur commonly with complete moles but are rare with partial moles. The malignant potential differs significantly: complete moles progress to gestational trophoblastic neoplasia in 15-20% of cases, while partial moles progress in only 1-5%. Clinical presentation of molar pregnancy includes several characteristic features. Vaginal bleeding in the first trimester is the most common presenting symptom. The uterus may be larger than expected for gestational age, particularly with complete moles. Markedly elevated beta-hCG levels may cause severe hyperemesis gravidarum and, rarely, hyperthyroidism due to cross-reactivity between hCG and TSH receptors. Preeclampsia occurring before 20 weeks gestation, though rare, strongly suggests molar pregnancy. Passage of grape-like vesicles is pathognomonic but uncommon in modern practice due to earlier diagnosis. Diagnostic evaluation confirms molar pregnancy and assesses for complications. Transvaginal ultrasound of complete mole shows a characteristic snowstorm or cluster of grapes appearance with no fetal parts. Partial mole ultrasound shows an abnormal placenta with Swiss cheese or moth-eaten appearance and often abnormal fetal structures. Markedly elevated beta-hCG supports the diagnosis. Chest X-ray evaluates for pulmonary metastases. Thyroid function tests identify hyperthyroidism requiring treatment. Pathologic examination of evacuated tissue confirms the diagnosis and differentiates complete from partial mole. Panel A: Spectrum diagram of gestational trophoblastic disease from benign molar pregnancy through invasive mole to malignant choriocarcinoma with transition rates. Panel B: Comparison chart of complete versus partial molar pregnancy including karyotype, beta-hCG levels, theca lutein cysts, and malignant potential percentages. Panel C: Clinical presentation constellation showing vaginal bleeding, large for dates uterus, hyperemesis, hyperthyroidism, and early preeclampsia. Panel D: Ultrasound appearance comparison of complete mole (snowstorm pattern), partial mole (Swiss cheese placenta with fetal parts), and normal early pregnancy. --- ### VIII. GTD Management Treatment of molar pregnancy requires suction dilation and curettage as the standard approach. This procedure evacuates the uterine contents while preserving the uterus for future fertility. Induction of labor or prostaglandin administration should be avoided due to risk of trophoblastic embolization. Rh immune globulin is administered to Rh-negative patients as with other pregnancy losses. Effective contraception must be used during the surveillance period to allow accurate beta-hCG monitoring and distinguish from new pregnancy. Combined hormonal contraceptives are safe and commonly used during surveillance. Post-evacuation surveillance monitors for persistent or malignant disease through serial beta-hCG measurement. Weekly beta-hCG levels are obtained until undetectable for three consecutive weeks. Subsequently, monthly levels continue for six months after undetectable for complete moles or three months for partial moles. Reliable contraception throughout surveillance is essential to avoid confusing rising hCG from new pregnancy with gestational trophoblastic neoplasia. Once surveillance is complete with sustained undetectable levels, patients may attempt pregnancy with reassurance of normal pregnancy outcomes. Indications for chemotherapy identify patients who have developed gestational trophoblastic neoplasia requiring treatment. A plateau in beta-hCG levels, defined as less than 10% decline over three consecutive weekly measurements, indicates persistent disease. Any rise in beta-hCG levels during surveillance requires treatment. Identification of metastatic disease to lung, vagina, brain, or liver necessitates chemotherapy. Histologic diagnosis of choriocarcinoma requires treatment regardless of beta-hCG trend. Beta-hCG remaining elevated more than six months after evacuation indicates persistent disease. Single-agent methotrexate or actinomycin-D achieves cure in most low-risk cases, while multi-agent chemotherapy treats high-risk disease. Prognosis for gestational trophoblastic disease is excellent with appropriate treatment and surveillance. Molar pregnancy treated with evacuation and surveillance carries a very favorable prognosis, with most patients completing surveillance uneventfully. Even gestational trophoblastic neoplasia has high cure rates exceeding 90% with appropriate chemotherapy. Future pregnancy after completing surveillance is not associated with increased risk of molar pregnancy or complications. Patients should be counseled about the importance of compliance with surveillance to ensure early detection of any persistent disease. The risk of molar pregnancy in subsequent pregnancies is approximately 1-2%, slightly higher than the baseline population risk. Panel A: Suction D&C technique illustration with key steps, avoidance of induction, and concurrent RhoGAM and contraception requirements. Panel B: Surveillance protocol timeline showing weekly beta-hCG until undetectable, then monthly for 6 months (complete) or 3 months (partial), with contraception throughout. Panel C: Chemotherapy indication criteria showing plateau, rise, metastases, choriocarcinoma histology, and persistent elevation beyond 6 months. Panel D: Prognosis counseling diagram showing excellent cure rates, future pregnancy outcomes, and recurrence risk estimates. --- ### IX. Hyperemesis Gravidarum Hyperemesis gravidarum represents the severe end of the nausea and vomiting of pregnancy spectrum and requires medical treatment to prevent maternal and fetal complications. The condition is defined by severe, persistent nausea and vomiting that is not responsive to usual first-line measures, weight loss exceeding 5% of pre-pregnancy weight, and dehydration with ketonuria. Symptom onset typically occurs at 6-8 weeks gestation with peak severity at 9-12 weeks. Unlike typical nausea and vomiting of pregnancy, which affects up to 80% of pregnant women with minimal adverse effects, hyperemesis gravidarum significantly impacts maternal quality of life and may affect fetal outcomes if untreated. Complications of hyperemesis gravidarum result from prolonged vomiting, dehydration, and nutritional deficiency. Dehydration causes electrolyte abnormalities including hypokalemia, hyponatremia, and hypochloremic metabolic alkalosis. Wernicke encephalopathy from thiamine deficiency represents a serious but preventable complication, making thiamine supplementation mandatory in hospitalized patients receiving intravenous fluids. Significant weight loss leads to nutritional deficiencies affecting both mother and fetus. Psychological effects including depression and anxiety compound the physical suffering. With appropriate treatment, fetal outcomes are generally favorable, though severe untreated cases may have increased small for gestational age infants. Evaluation of hyperemesis gravidarum includes assessment of disease severity and exclusion of other causes of vomiting. Urinalysis documents ketonuria and specific gravity indicating dehydration status. Serum electrolytes identify hypokalemia, hyponatremia, and other abnormalities requiring correction. Liver function tests may show mild transaminase elevation in severe cases. Thyroid-stimulating hormone should be checked as gestational hyperthyroidism from high hCG levels can contribute to symptoms. Pelvic ultrasound excludes molar pregnancy and multiple gestations, both associated with higher hCG levels and more severe nausea. Treatment of hyperemesis gravidarum follows a stepwise approach based on severity. Mild cases are managed with dietary modifications including small frequent meals, avoidance of triggers, and first-line antiemetics such as pyridoxine (vitamin B6) with or without doxylamine. Moderate cases require additional antiemetics including ondansetron or promethazine and may benefit from outpatient intravenous hydration. Severe cases require hospitalization for intravenous fluids, electrolyte repletion, thiamine supplementation, and antiemetic therapy. Refractory cases may require corticosteroids or, rarely, total parenteral nutrition for nutritional support when oral intake remains impossible. Panel A: Severity spectrum from nausea and vomiting of pregnancy (common, mild) through hyperemesis gravidarum (severe, treatment-requiring) with distinguishing features. Panel B: Complication cascade diagram showing vomiting leading to dehydration, electrolyte abnormalities, and nutritional deficiency with specific complications at each level. Panel C: Evaluation checklist including urinalysis, electrolytes, liver function, TSH, and ultrasound with expected findings and their significance. Panel D: Stepwise treatment algorithm from dietary modifications and vitamin B6 through antiemetics, IV hydration, and hospitalization with escalation criteria. --- ### X. Subchorionic Hematoma and Other First Trimester Issues Subchorionic hematoma represents blood collection between the chorion and the uterine wall and is a common finding on first trimester ultrasound. This condition may present with vaginal bleeding but is often discovered incidentally on routine ultrasound. The appearance on ultrasound is a crescent-shaped hypoechoic or anechoic collection adjacent to the gestational sac, lifting the chorion from the decidua. Prognosis depends primarily on hematoma size relative to gestational sac size, with small hematomas generally resolving without complication. Large hematomas may be associated with increased risk of miscarriage, preterm delivery, or placental abruption. Management of subchorionic hematoma is primarily expectant with close monitoring. Pelvic rest, including avoidance of intercourse and strenuous activity, is commonly recommended though evidence for benefit is limited. Serial ultrasound examinations document resolution or progression. Most small hematomas resolve spontaneously by the second trimester without adverse outcomes. Warning signs requiring evaluation include increasing bleeding, significant pain, or signs of threatened abortion. Progesterone supplementation is sometimes prescribed though evidence for efficacy is unclear. Patient counseling should include reassurance that most cases resolve favorably while acknowledging the uncertainty about outcomes. Cervical insufficiency, though primarily a second trimester complication, may be identified or suspected in the first trimester based on history. Risk factors include prior cervical surgery such as loop electrosurgical excision procedure (LEEP), multiple prior dilations, and history of cervical insufficiency with prior pregnancy loss. The classic presentation is painless cervical dilation in the second trimester leading to preterm delivery or pregnancy loss. Transvaginal ultrasound cervical length measurement identifies short cervix warranting intervention. Treatment options include cervical cerclage placed prophylactically in patients with prior history or in response to short cervix, and vaginal progesterone supplementation. First trimester screening abnormalities identified on cell-free DNA testing or combined first trimester screening require appropriate counseling and follow-up. Increased nuchal translucency warrants detailed fetal anatomic survey, fetal echocardiography, and consideration of diagnostic testing such as chorionic villus sampling. Abnormal non-invasive prenatal testing results require confirmatory diagnostic testing before any pregnancy decisions. Risk figures should be communicated in understandable terms, and genetic counseling services provide valuable support. Corpus luteum cysts, normal findings in early pregnancy that support progesterone production, are occasionally symptomatic but typically resolve by 10-12 weeks as the placenta assumes hormonal function. Panel A: Ultrasound appearance of subchorionic hematoma showing crescent-shaped collection between chorion and uterine wall with size classification and prognosis correlation. Panel B: Subchorionic hematoma management algorithm including expectant care, pelvic rest recommendations, serial ultrasound schedule, and warning signs for evaluation. Panel C: Cervical insufficiency risk factors, second trimester presentation, ultrasound cervical length assessment, and treatment options including cerclage and progesterone. Panel D: First trimester screening follow-up flowchart showing increased NT evaluation, abnormal NIPT counseling, and corpus luteum cyst natural history. --- ## Summary - First trimester bleeding: occurs in 20-40% of pregnancies; approximately 50% continue to viable pregnancy - Discriminatory zone: beta-hCG 1500-2000 mIU/mL at which intrauterine pregnancy should be visible on transvaginal ultrasound - Ectopic pregnancy risk factors: prior ectopic (highest), PID, tubal surgery, IUD with pregnancy, assisted reproduction - Ectopic treatment: methotrexate if stable, beta-hCG less than 5000, no cardiac activity; surgery if unstable or contraindicated - Miscarriage classification: threatened (closed os, viable), inevitable (open os), incomplete (partial passage), complete (all passed), missed (retained non-viable) - Miscarriage management: expectant (time), medical (misoprostol 800 mcg vaginal), or surgical (D&C) - Recurrent pregnancy loss: evaluate after 2 consecutive losses; APS, uterine anomaly, karyotype abnormalities - Complete mole: 46,XX entirely paternal; markedly elevated beta-hCG; 15-20% malignant potential - GTD surveillance: weekly beta-hCG until undetectable; monthly for 3-6 months; contraception throughout - Hyperemesis gravidarum: greater than 5% weight loss with ketonuria; IV fluids, antiemetics, thiamine supplementation --- ## Key Terms | Term | Definition | |------|------------| | Discriminatory zone | Beta-hCG level (1500-2000 mIU/mL) at which intrauterine pregnancy should be visible on transvaginal ultrasound | | Ectopic pregnancy | Implantation of pregnancy outside the uterine cavity, most commonly in the fallopian tube | | Missed abortion | Non-viable pregnancy retained in the uterus with closed cervical os | | Molar pregnancy | Abnormal placental development with hydropic villi; complete or partial | | Methotrexate | Folate antagonist used for medical management of ectopic pregnancy | | Hyperemesis gravidarum | Severe pregnancy nausea and vomiting requiring medical treatment | | Subchorionic hematoma | Blood collection between the chorion and uterine wall | | Antiphospholipid syndrome | Autoimmune condition causing recurrent pregnancy loss through placental thrombosis | --- *This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*